Fagron NV (EBR: FAGR)

Market Cap	1.32B
Revenue (ttm)	820.76M
Net Income (ttm)	77.94M
Shares Out	72.99M
EPS (ttm)	1.07
PE Ratio	16.99
Forward PE	14.48
Dividend	0.30 (1.66%)
Ex-Dividend Date	May 21, 2024

Volume	13,021
Average Volume	79,229
Open	18.12
Previous Close	18.12
Day's Range	17.94 - 18.12
52-Week Range	15.14 - 20.05
Beta	0.26
RSI	63.54
Earnings Date	Feb 20, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan use...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,282
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2023, Fagron NV's revenue was 762.99 million, an increase of 11.57% compared to the previous year's 683.88 million. Earnings were 70.55 million, an increase of 1.34%.